secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001628280-26-023222
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Pharmaceuticals General Counsel Timothy Williams resigns, effective Apr 10, 2026
--------------------------------------------------------------------------------

- Timothy Williams resigns as SVP, General Counsel and Secretary, effective April 10, 2026.
- No successor or interim replacement announced; search process not disclosed.
- Resignation is to pursue other endeavors; no conflict or disagreement noted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828026023222/0001628280-26-023222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828026023222/vnda-20260329.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-023222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer